<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">36076282</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Protein citrullination marks myelin protein aggregation and disease progression in mouse ALS models.</ArticleTitle><Pagination><StartPage>135</StartPage><MedlinePgn>135</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-022-01433-5</ELocationID><Abstract><AbstractText>Increased protein citrullination (PC) and dysregulated protein arginine deiminase (PAD) activity have been observed in several neurodegenerative diseases. PC is a posttranslational modification catalyzed by the PADs. PC converts peptidyl-arginine to peptidyl-citrulline, thereby reducing the positive charges and altering structure and function of proteins. Of the five PADs, PAD2 is the dominant isoform in the central nervous system (CNS). Abnormal PC and PAD dysregulation are associated with numerous pathological conditions, including inflammatory diseases and neurodegeneration. Animal model studies have shown therapeutic efficacy from inhibition of PADs, thus suggesting a role of PC in pathogenesis. To determine whether PC contribute to amyotrophic lateral sclerosis (ALS), a deadly neurodegenerative disease characterized by loss of motor neurons, paralysis, and eventual death, we investigated alterations of PC and PAD2 in two different transgenic mouse models of ALS expressing human mutant SOD1<sup>G93A</sup> and PFN1<sup>C71G</sup>, respectively. PC and PAD2 expression are altered dynamically in the spinal cord during disease progression in both models. PC and PAD2 increase progressively in astrocytes with the development of reactive astrogliosis, while decreasing in neurons. Importantly, in the spinal cord white matter, PC accumulates in protein aggregates that contain the myelin proteins PLP and MBP. PC also accumulates progressively in insoluble protein fractions during disease progression. Finally, increased PC and PAD2 expression spatially correlate with areas of the CNS with the most severe motor neuron degeneration. These results suggest that altered PC is an integral part of the neurodegenerative process and potential biomarkers for disease progression in ALS. Moreover, increased PC may contribute to disease-associated processes such as myelin protein aggregation, myelin degeneration, and astrogliosis.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Issa O</ForeName><Initials>IO</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Astellas Pharma, 33 Locke Dr, Marlborough, MA, 01752, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsi</LastName><ForeName>Sepideh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilvawala</LastName><ForeName>Ronak</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scorpion Therapeutics, 1 Winthrop Square, Boston, MA, 02110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Chemical Biology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zuoshang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-1209-334X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School, Worcester, MA, 01605, USA. zuoshang.xu@umassmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM113117</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118145</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM118112</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009185">Myelin Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495738">PFN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051304">Profilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076302" MajorTopicYN="N">Citrullination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009185" MajorTopicYN="N">Myelin Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051304" MajorTopicYN="N">Profilins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Astrogliosis</Keyword><Keyword MajorTopicYN="N">Deimination</Keyword><Keyword MajorTopicYN="N">Myelin degeneration</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">Protein aggregation</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare that are relevant to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36076282</ArticleId><ArticleId IdType="pmc">PMC9458309</ArticleId><ArticleId IdType="doi">10.1186/s40478-022-01433-5</ArticleId><ArticleId IdType="pii">10.1186/s40478-022-01433-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, Petrucelli L. Genetic convergence brings clarity to the enigmatic red line in ALS. Neuron. 2019;101:1057&#x2013;1069. doi: 10.1016/j.neuron.2019.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.032</ArticleId><ArticleId IdType="pubmed">30897357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin AMG, Shadfar S, Vidal M, Jamali MS, Atkin JD. Motor neuron susceptibility in ALS/FTD. Front Neurosci. 2019;13:532. doi: 10.3389/fnins.2019.00532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00532</ArticleId><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Ahmad TK, Gozda K, Truong J, Kong J, Namaka M. Implications of white matter damage in amyotrophic lateral sclerosis (Review) Mol Med Rep. 2017;16:4379&#x2013;4392. doi: 10.3892/mmr.2017.7186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7186</ArticleId><ArticleId IdType="pmc">PMC5646997</ArticleId><ArticleId IdType="pubmed">28791401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal S, Thompson PR. Protein arginine deiminases (PADs): biochemistry and chemical biology of protein citrullination. Acc Chem Res. 2019;52:818&#x2013;832. doi: 10.1021/acs.accounts.9b00024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.9b00024</ArticleId><ArticleId IdType="pmc">PMC6443095</ArticleId><ArticleId IdType="pubmed">30844238</ArticleId></ArticleIdList></Reference><Reference><Citation>Witalison EE, Thompson PR, Hofseth LJ. Protein arginine deiminases and associated citrullination: physiological functions and diseases associated with dysregulation. Curr Drug Targets. 2015;16:700&#x2013;710. doi: 10.2174/1389450116666150202160954.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450116666150202160954</ArticleId><ArticleId IdType="pmc">PMC4520219</ArticleId><ArticleId IdType="pubmed">25642720</ArticleId></ArticleIdList></Reference><Reference><Citation>Briot J, Simon M, Mechin MC. Deimination, intermediate filaments and associated proteins. Int J Mol Sci. 2020 doi: 10.3390/ijms21228746.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228746</ArticleId><ArticleId IdType="pmc">PMC7699402</ArticleId><ArticleId IdType="pubmed">33228136</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann J, Clancy KW, Thompson PR. Chemical biology of protein arginine modifications in epigenetic regulation. Chem Rev. 2015;115:5413&#x2013;5461. doi: 10.1021/acs.chemrev.5b00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.5b00003</ArticleId><ArticleId IdType="pmc">PMC4463550</ArticleId><ArticleId IdType="pubmed">25970731</ArticleId></ArticleIdList></Reference><Reference><Citation>Harauz G, Musse AA. A tale of two citrullines&#x2013;structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem Res. 2007;32:137&#x2013;158. doi: 10.1007/s11064-006-9108-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9108-9</ArticleId><ArticleId IdType="pubmed">16900293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilvawala R, Thompson PR. Peptidyl arginine deiminases: detection and functional analysis of protein citrullination. Curr Opin Struct Biol. 2019;59:205&#x2013;215. doi: 10.1016/j.sbi.2019.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2019.01.024</ArticleId><ArticleId IdType="pmc">PMC6717693</ArticleId><ArticleId IdType="pubmed">30833201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisaki M, Sugawara K. Properties of peptidylarginine deiminase from the epidermis of newborn rats. J Biochem. 1981;89:257&#x2013;263. doi: 10.1093/oxfordjournals.jbchem.a133189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.jbchem.a133189</ArticleId><ArticleId IdType="pubmed">7217033</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K, Proost P. Insights into peptidylarginine deiminase expression and citrullination pathways. Trends Cell Biol. 2022 doi: 10.1016/j.tcb.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2022.01.014</ArticleId><ArticleId IdType="pubmed">35197210</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada N, Handa S, Uchida Y, Fukuda M, Maruyama N, Asaga H, Choi EK, Lee J, Ishigami A. Developmental and age-related changes of peptidylarginine deiminase 2 in the mouse brain. J Neurosci Res. 2010;88:798&#x2013;806. doi: 10.1002/jnr.22255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22255</ArticleId><ArticleId IdType="pubmed">19830834</ArticleId></ArticleIdList></Reference><Reference><Citation>Christophorou MA. The virtues and vices of protein citrullination. R Soc Open Sci. 2022;9:220125. doi: 10.1098/rsos.220125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsos.220125</ArticleId><ArticleId IdType="pmc">PMC9174705</ArticleId><ArticleId IdType="pubmed">35706669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesielski O, Biesiekierska M, Panthu B, Soszynski M, Pirola L, Balcerczyk A. Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives. Cell Mol Life Sci. 2022;79:94. doi: 10.1007/s00018-022-04126-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04126-3</ArticleId><ArticleId IdType="pmc">PMC8788905</ArticleId><ArticleId IdType="pubmed">35079870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigami A, Ohsawa T, Hiratsuka M, Taguchi H, Kobayashi S, Saito Y, Murayama S, Asaga H, Toda T, Kimura N, et al. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci Res. 2005;80:120&#x2013;128. doi: 10.1002/jnr.20431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20431</ArticleId><ArticleId IdType="pubmed">15704193</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang B, Jin JK, Jeon YC, Cho HJ, Ishigami A, Choi KC, Carp RI, Maruyama N, Kim YS, Choi EK. Involvement of peptidylarginine deiminase-mediated post-translational citrullination in pathogenesis of sporadic Creutzfeldt-Jakob disease. Acta Neuropathol. 2010;119:199&#x2013;210. doi: 10.1007/s00401-009-0625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0625-x</ArticleId><ArticleId IdType="pubmed">20013286</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang B, Kim E, Choi JK, Jin JK, Kim JI, Ishigami A, Maruyama N, Carp RI, Kim YS, Choi EK. Accumulation of citrullinated proteins by up-regulated peptidylarginine deiminase 2 in brains of scrapie-infected mice: a possible role in pathogenesis. Am J Pathol. 2008;173:1129&#x2013;1142. doi: 10.2353/ajpath.2008.080388.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080388</ArticleId><ArticleId IdType="pmc">PMC2543080</ArticleId><ArticleId IdType="pubmed">18787103</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang B, Shin HY, Choi JK, du Nguyen PT, Jeong BH, Ishigami A, Maruyama N, Carp RI, Kim YS, Choi EK. Subcellular localization of peptidylarginine deiminase 2 and citrullinated proteins in brains of scrapie-infected mice: nuclear localization of PAD2 and membrane fraction-enriched citrullinated proteins. J Neuropathol Exp Neurol. 2011;70:116&#x2013;124. doi: 10.1097/NEN.0b013e318207559e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318207559e</ArticleId><ArticleId IdType="pubmed">21343880</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange S, Rocha-Ferreira E, Thei L, Mawjee P, Bennett K, Thompson PR, Subramanian V, Nicholas AP, Peebles D, Hristova M, et al. Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates. J Neurochem. 2014;130:555&#x2013;562. doi: 10.1111/jnc.12744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12744</ArticleId><ArticleId IdType="pmc">PMC4185393</ArticleId><ArticleId IdType="pubmed">24762056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus RC, Buonora JE, Flora MN, Freedy JG, Holstein GR, Martinelli GP, Jacobowitz DM, Mueller GP. Protein citrullination: a proposed mechanism for pathology in traumatic brain injury. Front Neurol. 2015;6:204. doi: 10.3389/fneur.2015.00204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00204</ArticleId><ArticleId IdType="pmc">PMC4585288</ArticleId><ArticleId IdType="pubmed">26441823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch HM, Probert L, Casaccia-Bonnefil P, Moscarello MA. Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J Neurosci. 2006;26:11387&#x2013;11396. doi: 10.1523/JNEUROSCI.3349-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3349-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674531</ArticleId><ArticleId IdType="pubmed">17079667</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscarello MA, Pritzker L, Mastronardi FG, Wood DD. Peptidylarginine deiminase: a candidate factor in demyelinating disease. J Neurochem. 2002;81:335&#x2013;343. doi: 10.1046/j.1471-4159.2002.00834.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.00834.x</ArticleId><ArticleId IdType="pubmed">12064481</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas AP. Dual immunofluorescence study of citrullinated proteins in Parkinson diseased substantia nigra. Neurosci Lett. 2011;495:26&#x2013;29. doi: 10.1016/j.neulet.2011.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2011.03.028</ArticleId><ArticleId IdType="pubmed">21414385</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Subramanian V, O'Dell AA, Yalavarthi S, Zhao W, Smith CK, Hodgin JB, Thompson PR, Kaplan MJ. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015;74:2199&#x2013;2206. doi: 10.1136/annrheumdis-2014-205365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205365</ArticleId><ArticleId IdType="pmc">PMC4320672</ArticleId><ArticleId IdType="pubmed">25104775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange S, Gogel S, Leung KY, Vernay B, Nicholas AP, Causey CP, Thompson PR, Greene ND, Ferretti P. Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev Biol. 2011;355:205&#x2013;214. doi: 10.1016/j.ydbio.2011.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2011.04.015</ArticleId><ArticleId IdType="pmc">PMC4768803</ArticleId><ArticleId IdType="pubmed">21539830</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscarello MA, Lei H, Mastronardi FG, Winer S, Tsui H, Li Z, Ackerley C, Zhang L, Raijmakers R, Wood DD. Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis. Dis Model Mech. 2013;6:467&#x2013;478. doi: 10.1242/dmm.010520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.010520</ArticleId><ArticleId IdType="pmc">PMC3597028</ArticleId><ArticleId IdType="pubmed">23118341</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodre FMC, Bissenova S, Bruggeman Y, Tilvawala R, Cook DP, Berthault C, Mondal S, Callebaut A, You S, Scharfmann R, et al. Peptidylarginine deiminase inhibition prevents diabetes development in NOD mice. Diabetes. 2021;70:516&#x2013;528. doi: 10.2337/db20-0421.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db20-0421</ArticleId><ArticleId IdType="pmc">PMC7881854</ArticleId><ArticleId IdType="pubmed">33203696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Rebman AW, Johnson TP, Wang H, Yang T, Colantuoni C, Bhargava P, Levy M, Calabresi PA, Aucott JN, et al. Peptidylarginine deiminase 2 autoantibodies are linked to less severe disease in multiple sclerosis and post-treatment lyme disease. Front Neurol. 2022;13:874211. doi: 10.3389/fneur.2022.874211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.874211</ArticleId><ArticleId IdType="pmc">PMC9207393</ArticleId><ArticleId IdType="pubmed">35734473</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Danielson EW, Qiao T, Metterville J, Brown RH, Jr, Landers JE, Xu Z. Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc Natl Acad Sci USA. 2016;113:E6209&#x2013;E6218. doi: 10.1073/pnas.1605964113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605964113</ArticleId><ArticleId IdType="pmc">PMC5068285</ArticleId><ArticleId IdType="pubmed">27681617</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaga H, Senshu T. Combined biochemical and immunocytochemical analyses of postmortem protein deimination in the rat spinal cord. Cell Biol Int. 1993;17:525&#x2013;532. doi: 10.1006/cbir.1993.1094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cbir.1993.1094</ArticleId><ArticleId IdType="pubmed">8339070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224:213&#x2013;232. doi: 10.1111/j.1365-2818.2006.01706.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.2006.01706.x</ArticleId><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol. 2011;300:C723&#x2013;742. doi: 10.1152/ajpcell.00462.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00462.2010</ArticleId><ArticleId IdType="pmc">PMC3074624</ArticleId><ArticleId IdType="pubmed">21209361</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantuma NP, Bott LC. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci. 2014;7:70. doi: 10.3389/fnmol.2014.00070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2014.00070</ArticleId><ArticleId IdType="pmc">PMC4117186</ArticleId><ArticleId IdType="pubmed">25132814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13:1396&#x2013;1403. doi: 10.1038/nn.2660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2007;104:2495&#x2013;2500. doi: 10.1073/pnas.0606201104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606201104</ArticleId><ArticleId IdType="pmc">PMC1790867</ArticleId><ArticleId IdType="pubmed">17277077</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas AP, Sambandam T, Echols JD, Barnum SR. Expression of citrullinated proteins in murine experimental autoimmune encephalomyelitis. J Comp Neurol. 2005;486:254&#x2013;266. doi: 10.1002/cne.20527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.20527</ArticleId><ArticleId IdType="pubmed">15844173</ArticleId></ArticleIdList></Reference><Reference><Citation>Palko SI, Saba NJ, Mullane E, Nicholas BD, Nagasaka Y, Ambati J, Gelfand BD, Ishigami A, Bargagna-Mohan P, Mohan R. Compartmentalized citrullination in Muller glial endfeet during retinal degeneration. Proc Natl Acad Sci USA. 2022 doi: 10.1073/pnas.2121875119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2121875119</ArticleId><ArticleId IdType="pmc">PMC8917347</ArticleId><ArticleId IdType="pubmed">35197297</ArticleId></ArticleIdList></Reference><Reference><Citation>Raijmakers R, Vogelzangs J, Croxford JL, Wesseling P, van Venrooij WJ, Pruijn GJ. Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. J Comp Neurol. 2005;486:243&#x2013;253. doi: 10.1002/cne.20529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.20529</ArticleId><ArticleId IdType="pubmed">15844172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang B, Ishigami A, Maruyama N, Carp RI, Kim YS, Choi EK. Peptidylarginine deiminase and protein citrullination in prion diseases: strong evidence of neurodegeneration. Prion. 2013;7:42&#x2013;46. doi: 10.4161/pri.22380.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.22380</ArticleId><ArticleId IdType="pmc">PMC3609049</ArticleId><ArticleId IdType="pubmed">23022892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998;18:3241&#x2013;3250. doi: 10.1523/JNEUROSCI.18-09-03241.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-09-03241.1998</ArticleId><ArticleId IdType="pmc">PMC6792665</ArticleId><ArticleId IdType="pubmed">9547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JB, Kong J, Nadler M, Xu Z. Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS) Glia. 1999;28:215&#x2013;224. doi: 10.1002/(SICI)1098-1136(199912)28:3&lt;215::AID-GLIA5&gt;3.0.CO;2-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-1136(199912)28:3&lt;215::AID-GLIA5&gt;3.0.CO;2-C</ArticleId><ArticleId IdType="pubmed">10559780</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;278. doi: 10.1016/0197-4580(95)00021-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Y, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12:15&#x2013;27. doi: 10.1038/nrneurol.2015.225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.225</ArticleId><ArticleId IdType="pubmed">26635213</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaga H, Ishigami A. Protein deimination in the rat brain after kainate administration: citrulline-containing proteins as a novel marker of neurodegeneration. Neurosci Lett. 2001;299:5&#x2013;8. doi: 10.1016/s0304-3940(00)01735-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3940(00)01735-3</ArticleId><ArticleId IdType="pubmed">11166924</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas AP. Dual immunofluorescence study of citrullinated proteins in Alzheimer diseased frontal cortex. Neurosci Lett. 2013;545:107&#x2013;111. doi: 10.1016/j.neulet.2013.04.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.04.028</ArticleId><ArticleId IdType="pmc">PMC3731154</ArticleId><ArticleId IdType="pubmed">23648390</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilvawala R, Nguyen SH, Maurais AJ, Nemmara VV, Nagar M, Salinger AJ, Nagpal S, Weerapana E, Thompson PR. The rheumatoid arthritis-associated citrullinome. Cell Chem Biol. 2018;25:691&#x2013;704 e696. doi: 10.1016/j.chembiol.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC6014894</ArticleId><ArticleId IdType="pubmed">29628436</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Perez KA, Dubois C, Nisbet RM, Li QX, Varghese S, Jin L, Birchall I, Streltsov VA, Vella LJ, et al. Citrullination of amyloid-beta peptides in Alzheimer's disease. ACS Chem Neurosci. 2021;12:3719&#x2013;3732. doi: 10.1021/acschemneuro.1c00474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00474</ArticleId><ArticleId IdType="pubmed">34519476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanikawa C, Ueda K, Suzuki A, Iida A, Nakamura R, Atsuta N, Tohnai G, Sobue G, Saichi N, Momozawa Y, et al. Citrullination of RGG motifs in FET proteins by PAD4 regulates protein aggregation and ALS susceptibility. Cell Rep. 2018;22:1473&#x2013;1483. doi: 10.1016/j.celrep.2018.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.01.031</ArticleId><ArticleId IdType="pubmed">29425503</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem. 2017;86:27&#x2013;68. doi: 10.1146/annurev-biochem-061516-045115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-061516-045115</ArticleId><ArticleId IdType="pubmed">28498720</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332&#x2013;1340. doi: 10.1038/s41593-018-0235-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0235-9</ArticleId><ArticleId IdType="pmc">PMC6432913</ArticleId><ArticleId IdType="pubmed">30250260</ArticleId></ArticleIdList></Reference><Reference><Citation>Alquezar C, Arya S, Kao AW. Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front Neurol. 2020;11:595532. doi: 10.3389/fneur.2020.595532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.595532</ArticleId><ArticleId IdType="pmc">PMC7817643</ArticleId><ArticleId IdType="pubmed">33488497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Biernat J, Mandelkow E. A current view on Tau protein phosphorylation in Alzheimer's disease. Curr Opin Neurobiol. 2021;69:131&#x2013;138. doi: 10.1016/j.conb.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2021.03.003</ArticleId><ArticleId IdType="pubmed">33892381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle FE, Akiyama H, Hisanaga S, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 2008;582:2899&#x2013;2904. doi: 10.1016/j.febslet.2008.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.07.027</ArticleId><ArticleId IdType="pubmed">18656473</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong L, Lee E, Kremmer E, Flatley A, Xu Y, Forman M, Troost D, Kretzschmar H, Trojanowski J, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Meng P, Zheng Y, Mao Y, Hu F. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem. 2011;116:248&#x2013;259. doi: 10.1111/j.1471-4159.2010.07098.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07098.x</ArticleId><ArticleId IdType="pubmed">21062285</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Yeh PA, Chiu HC, Tang CY, Tu BP. Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS ONE. 2011;6:e23075. doi: 10.1371/journal.pone.0023075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023075</ArticleId><ArticleId IdType="pmc">PMC3151276</ArticleId><ArticleId IdType="pubmed">21850253</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Xu YF, Ko LW, Yen SH, Petrucelli L. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener. 2010;5:33. doi: 10.1186/1750-1326-5-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-33</ArticleId><ArticleId IdType="pmc">PMC2941488</ArticleId><ArticleId IdType="pubmed">20804554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarcsa E, Marekov LN, Mei G, Melino G, Lee SC, Steinert PM. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem. 1996;271:30709&#x2013;30716. doi: 10.1074/jbc.271.48.30709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.48.30709</ArticleId><ArticleId IdType="pubmed">8940048</ArticleId></ArticleIdList></Reference><Reference><Citation>Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Fares C. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron. 2004;35:503&#x2013;542. doi: 10.1016/j.micron.2004.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micron.2004.04.005</ArticleId><ArticleId IdType="pubmed">15219899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn O, Siems SB, Kusch K, Hesse D, Jung RB, Liepold T, Uecker M, Sun T, Werner HB. The CNS myelin proteome: deep profile and persistence after post-mortem delay. Front Cell Neurosci. 2020;14:239. doi: 10.3389/fncel.2020.00239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00239</ArticleId><ArticleId IdType="pmc">PMC7466725</ArticleId><ArticleId IdType="pubmed">32973451</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777&#x2013;794. doi: 10.1007/s00401-013-1125-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1125-6</ArticleId><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Neuropathology of Alzheimer's disease and other dementias. Clin Geriatr Med. 2001;17:209&#x2013;228. doi: 10.1016/s0749-0690(05)70066-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0749-0690(05)70066-5</ArticleId><ArticleId IdType="pubmed">11375133</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187&#x2013;205. doi: 10.1007/s00401-017-1709-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1709-7</ArticleId><ArticleId IdType="pmc">PMC5508034</ArticleId><ArticleId IdType="pubmed">28401333</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscarello MA, Mastronardi FG, Wood DD. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res. 2007;32:251&#x2013;256. doi: 10.1007/s11064-006-9144-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9144-5</ArticleId><ArticleId IdType="pmc">PMC1794624</ArticleId><ArticleId IdType="pubmed">17031564</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Tan D, Piao H. Myelin basic protein citrullination in multiple sclerosis: a potential therapeutic target for the pathology. Neurochem Res. 2016;41:1845&#x2013;1856. doi: 10.1007/s11064-016-1920-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-016-1920-2</ArticleId><ArticleId IdType="pubmed">27097548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>